Zonisamide Capsules, USP, 100 mg, packaged in: a) 100-count bottle (NDC 68462-130-01); b) 500-count bottle (NDC 68462-130-05), Rx only, Manufactured by: Glenmark Pharmaceuticals, Inc., USA Monroe, NC 28110, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430
Published May 4, 2022 · Recall initiated: April 25, 2022
Summary
FDA records drug Class II recall D-0793-2022, published May 4, 2022 and initiated April 25, 2022. Recalling firm: Glenmark Pharmaceuticals Inc., USA; Status: Completed; Reported quantity: a) 7,044 bottles; b) 1,014 bottles; Lot: a) Lot #: 29200053, Exp 4/30/2023; b) Lot #: 29200054, Exp 4/30/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
cGMP deviations
What to do
Voluntary: Firm initiated · Letter
Get an email if ZONISAMIDE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- ZONISAMIDE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Distributor
- USA nationwide
- UPC
- 0368462130018
- Lot
- a) Lot #: 29200053, Exp 4/30/2023; b) Lot #: 29200054, Exp 4/30/2023
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAZonisamide Capsules, USP, 50 mg, packaged in 100-count bottles, Rx only, Manufactured by: GlenmarkMay 4, 2022
- FDAZonisamide Capsules USP, 25 mg, packaged in 100-count bottles, Rx Only, Manufactured by: GlenmarkMay 4, 2022
- FDALidocaine 2.5% and Prilocaine 2.5% Cream, USP, packaged in a) 5 g tubes (NDC 0591-2070-72), b) 30 g tubes (NDCMay 4, 2022
- FDANAD+ Nicotinamide Adenine Dinucleotide Lyophilized powder for reconstitution, Multi-Dose 500 mg Per Vial, RxMay 4, 2022
- FDACyanocobalamin Injection, USP, 1000 mcg per mL, For Intramuscular or Subcutaneous Use Only, 25 x 1 mL Vials,May 4, 2022
- FDAZonisamide Capsules USP 50 mg 100 Capsules Rx Only NDC 68462-129-01 Manufactured by: Glenmark PharmaceuticalsSeptember 29, 2021
Questions about this recall
Was Zonisamide Capsules, USP, 100 mg, packaged in: a) 100-count bottle (NDC 68462-130-01); b) 500-count bottle (NDC 68462-130-05), Rx only, Manufactured by: Glenmark Pharmaceuticals, Inc., USA Monroe, NC 28110, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430 recalled?
Yes. FDA published recall D-0793-2022 on May 4, 2022. Reported hazard: cGMP deviations
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: ZONISAMIDE. UPC: 0368462130018.